Erlotinib in Treating Patients With Barrett Esophagus
Part of paid clinical trials in Kansas City, Missouri.
- Sponsor
- Kansas City Veteran Affairs Medical Center
- Study ID
- NCT00566800
- Phase
- PHASE1
- Status
- Unknown
Conditions
- Esophageal Cancer
- Precancerous Condition
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- erlotinib hydrochloride — DRUG
- laboratory biomarker analysis — OTHER
- biopsy — PROCEDURE
Study Details
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with Barrett esophagus.
Key Dates
- Start date
- Jul 31, 2007
- Status verified
- Jan 2008
Study Design
- Enrollment
- 25 participants (estimated)
- Primary purpose
- TREATMENT
Primary Outcome Measure
Histologic regression of Barrett esophagus with high-grade dysplasia by chemoprevention with erlotinib hydrochloride
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Veterans Affairs Medical Center - Kansas City | Kansas City | Missouri | 64128 |
Find similar trials in Kansas City, MO
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)Recruiting · University of Colorado, Denver · Los Angeles, California
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid CancersRecruiting · University of Missouri-Columbia · Columbia, Missouri
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California